Evofuel CEO, Mr. Assaf Dotan will present the company’s new vision and branding at the confernece
Rehovot, Israel – May 21, 2019 – Evofuel Ltd., a company focused on securing the global demand for stable castor oil supply and a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that its CEO, Mr. Assaf Dotan, will present at 2019 ICOA Conference to take place on the 21st-23rd of May, 2019 in Dubrovnick, Croatia.
Mr. Assaf Dotan will present the company’s new vision and branding. The company’s new corporate presentation is available on Evogene’s website under the investor relations section: http://evogene.com/investor-relations/.
About Evogene Ltd.:
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and advanced computational technologies. Today, this platform is utilized by the Company to discover and develop innovative products in the following areas (via subsidiaries or divisions): ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions and human microbiome based therapeutics. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in its collaborations with world-leading companies such as BASF, Bayer Corteva, and ICL. For more information, please visit www.evogene.com
Forward Looking Statements:
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’s control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact:
Nir Zalik
IR/PR Manager
E: IR@evogene.com
T: (+972)-8-931-1963
US Investor Relations
Vivian Cervantes
PCG Advisory
E: vivian@pcgadvisory.com
T: 646-863-6274